- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT04527549
Testing av dabrafenib og trametinib med eller uten hydroksyklorokin i stadium IIIC eller IV BRAF V600E/K melanom
BAMM2 (BRAF, Autophagy, MEK Inhibition in Melanoma)-studien: En randomisert dobbeltblind fase II-studie av dabrafenib og trametinib med eller uten hydroksyklorokin i avansert BRAF V600E/K melanom
This phase II trial investigates how well adding hydroxychloroquine to the standard treatment of dabrafenib and trametinib works to overcome resistance and delay disease progression in treating patients with stage IIIC or IV BRAF V600E/K melanoma. Hydroxychloroquine may cause cell death in tumor cells that rely on a process called "autophagy" for survival. Dabrafenib and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving hydroxychloroquine together with dabrafenib and trametinib may work better than dabrafenib and trametinib alone to shrink and stabilize the cancer.
Studieoversikt
Status
Forhold
Detaljert beskrivelse
PRIMARY OBJECTIVE:
I. To determine the rate of one year progression-free survival (PFS) when hydroxychloroquine sulfate (hydroxychloroquine) or placebo is added to dabrafenib mesylate (dabrafenib) and trametinib dimethyl sulfoxide (trametinib) in advanced BRAFV600E/K melanoma with elevated lactate dehydrogenase (LDH).
SECONDARY OBJECTIVES:
I. To compare the PFS of both arms. II. To evaluate the best overall response rate by treatment arm. III. To evaluate the complete response (CR) rate by treatment arm. IV. To evaluate the adverse event rate by treatment arm. V. To evaluate overall survival (OS) by treatment arm.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM A: Patients receive dabrafenib mesylate orally (PO) twice daily (BID), trametinib dimethyl sulfoxide PO once daily (QD), and hydroxychloroquine sulfate PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
ARM B: Patients receive dabrafenib mesylate PO BID, trametinib dimethyl sulfoxide PO QD, and placebo PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up for 1 year.
Studietype
Registrering (Faktiske)
Fase
- Fase 2
Kontakter og plasseringer
Studiesteder
-
-
Alaska
-
Anchorage, Alaska, Forente stater, 98508
- Anchorage Associates in Radiation Medicine
-
Anchorage, Alaska, Forente stater, 99508
- Alaska Breast Care and Surgery LLC
-
Anchorage, Alaska, Forente stater, 99508
- Alaska Oncology and Hematology LLC
-
Anchorage, Alaska, Forente stater, 99508
- Alaska Women's Cancer Care
-
Anchorage, Alaska, Forente stater, 99508
- Anchorage Oncology Centre
-
Anchorage, Alaska, Forente stater, 99508
- Katmai Oncology Group
-
Anchorage, Alaska, Forente stater, 99508
- Providence Alaska Medical Center
-
Anchorage, Alaska, Forente stater, 99504
- Anchorage Radiation Therapy Center
-
-
Arizona
-
Phoenix, Arizona, Forente stater, 85054
- Mayo Clinic Hospital in Arizona
-
Phoenix, Arizona, Forente stater, 85004
- Cancer Center at Saint Joseph's
-
Scottsdale, Arizona, Forente stater, 85259
- Mayo Clinic in Arizona
-
-
Arkansas
-
Fort Smith, Arkansas, Forente stater, 72903
- Mercy Hospital Fort Smith
-
Hot Springs, Arkansas, Forente stater, 71913
- CHI Saint Vincent Cancer Center Hot Springs
-
-
California
-
Arroyo Grande, California, Forente stater, 93420
- Mission Hope Medical Oncology - Arroyo Grande
-
Burbank, California, Forente stater, 91505
- Providence Saint Joseph Medical Center/Disney Family Cancer Center
-
Los Angeles, California, Forente stater, 90048
- Cedars Sinai Medical Center
-
San Luis Obispo, California, Forente stater, 93401
- Pacific Central Coast Health Center-San Luis Obispo
-
Santa Maria, California, Forente stater, 93444
- Mission Hope Medical Oncology - Santa Maria
-
-
Colorado
-
Colorado Springs, Colorado, Forente stater, 80907
- Penrose-Saint Francis Healthcare
-
Colorado Springs, Colorado, Forente stater, 80907
- Rocky Mountain Cancer Centers-Penrose
-
Colorado Springs, Colorado, Forente stater, 80923
- Saint Francis Cancer Center
-
Denver, Colorado, Forente stater, 80210
- Porter Adventist Hospital
-
Durango, Colorado, Forente stater, 81301
- Mercy Medical Center
-
Durango, Colorado, Forente stater, 81301
- Southwest Oncology PC
-
Lakewood, Colorado, Forente stater, 80228
- Saint Anthony Hospital
-
Littleton, Colorado, Forente stater, 80122
- Littleton Adventist Hospital
-
Longmont, Colorado, Forente stater, 80501
- Longmont United Hospital
-
Longmont, Colorado, Forente stater, 80501
- Rocky Mountain Cancer Centers-Longmont
-
Parker, Colorado, Forente stater, 80138
- Parker Adventist Hospital
-
Pueblo, Colorado, Forente stater, 81004
- Saint Mary Corwin Medical Center
-
-
Delaware
-
Frankford, Delaware, Forente stater, 19945
- Beebe South Coastal Health Campus
-
Lewes, Delaware, Forente stater, 19958
- Beebe Medical Center
-
Newark, Delaware, Forente stater, 19713
- Helen F Graham Cancer Center
-
Newark, Delaware, Forente stater, 19713
- Delaware Clinical and Laboratory Physicians PA
-
Newark, Delaware, Forente stater, 19713
- Medical Oncology Hematology Consultants PA
-
Newark, Delaware, Forente stater, 19718
- Christiana Care Health System-Christiana Hospital
-
Rehoboth Beach, Delaware, Forente stater, 19971
- Beebe Health Campus
-
Seaford, Delaware, Forente stater, 19973
- TidalHealth Nanticoke / Allen Cancer Center
-
Wilmington, Delaware, Forente stater, 19801
- Christiana Care Health System-Wilmington Hospital
-
-
District of Columbia
-
Washington D.C., District of Columbia, Forente stater, 20007
- MedStar Georgetown University Hospital
-
-
Florida
-
Aventura, Florida, Forente stater, 33180
- UM Sylvester Comprehensive Cancer Center at Aventura
-
Coral Gables, Florida, Forente stater, 33146
- UM Sylvester Comprehensive Cancer Center at Coral Gables
-
Deerfield Beach, Florida, Forente stater, 33442
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach
-
Miami, Florida, Forente stater, 33136
- University of Miami Miller School of Medicine-Sylvester Cancer Center
-
Miami, Florida, Forente stater, 33176
- UM Sylvester Comprehensive Cancer Center at Kendall
-
Plantation, Florida, Forente stater, 33324
- UM Sylvester Comprehensive Cancer Center at Plantation
-
-
Idaho
-
Boise, Idaho, Forente stater, 83712
- Saint Luke's Cancer Institute - Boise
-
Fruitland, Idaho, Forente stater, 83619
- Saint Luke's Cancer Institute - Fruitland
-
Meridian, Idaho, Forente stater, 83642
- Saint Luke's Cancer Institute - Meridian
-
Nampa, Idaho, Forente stater, 83686
- Saint Luke's Cancer Institute - Nampa
-
Twin Falls, Idaho, Forente stater, 83301
- Saint Luke's Cancer Institute - Twin Falls
-
-
Illinois
-
Alton, Illinois, Forente stater, 62002
- Saint Anthony's Health
-
Aurora, Illinois, Forente stater, 60504
- Rush - Copley Medical Center
-
Burr Ridge, Illinois, Forente stater, 60527
- Loyola Center for Health at Burr Ridge
-
Danville, Illinois, Forente stater, 61832
- Carle on Vermilion
-
Effingham, Illinois, Forente stater, 62401
- Carle Physician Group-Effingham
-
Homer Glen, Illinois, Forente stater, 60491
- Loyola Medicine Homer Glen
-
Mattoon, Illinois, Forente stater, 61938
- Carle Physician Group-Mattoon/Charleston
-
Maywood, Illinois, Forente stater, 60153
- Loyola University Medical Center
-
Melrose Park, Illinois, Forente stater, 60160
- Marjorie Weinberg Cancer Center at Loyola-Gottlieb
-
Mount Vernon, Illinois, Forente stater, 62864
- Good Samaritan Regional Health Center
-
Urbana, Illinois, Forente stater, 61801
- Carle Cancer Center
-
Urbana, Illinois, Forente stater, 61801
- The Carle Foundation Hospital
-
Yorkville, Illinois, Forente stater, 60560
- Rush-Copley Healthcare Center
-
-
Indiana
-
Richmond, Indiana, Forente stater, 47374
- Reid Health
-
-
Iowa
-
Ames, Iowa, Forente stater, 50010
- McFarland Clinic PC - Ames
-
Ames, Iowa, Forente stater, 50010
- Mary Greeley Medical Center
-
Boone, Iowa, Forente stater, 50036
- McFarland Clinic PC-Boone
-
Carroll, Iowa, Forente stater, 51401
- Saint Anthony Regional Hospital
-
Clive, Iowa, Forente stater, 50325
- Mercy Cancer Center-West Lakes
-
Clive, Iowa, Forente stater, 50325
- Medical Oncology and Hematology Associates-West Des Moines
-
Council Bluffs, Iowa, Forente stater, 51503
- Alegent Health Mercy Hospital
-
Creston, Iowa, Forente stater, 50801
- Greater Regional Medical Center
-
Des Moines, Iowa, Forente stater, 50309
- Iowa Methodist Medical Center
-
Des Moines, Iowa, Forente stater, 50314
- Mercy Medical Center - Des Moines
-
Des Moines, Iowa, Forente stater, 50309
- Medical Oncology and Hematology Associates-Des Moines
-
Des Moines, Iowa, Forente stater, 50314
- Broadlawns Medical Center
-
Des Moines, Iowa, Forente stater, 50314
- Mission Cancer and Blood - Laurel
-
Des Moines, Iowa, Forente stater, 50316
- Iowa Lutheran Hospital
-
Fort Dodge, Iowa, Forente stater, 50501
- McFarland Clinic PC-Trinity Cancer Center
-
Fort Dodge, Iowa, Forente stater, 50501
- Trinity Regional Medical Center
-
Jefferson, Iowa, Forente stater, 50129
- McFarland Clinic PC-Jefferson
-
Marshalltown, Iowa, Forente stater, 50158
- McFarland Clinic PC-Marshalltown
-
West Des Moines, Iowa, Forente stater, 50266-7700
- Methodist West Hospital
-
West Des Moines, Iowa, Forente stater, 50266
- Mercy Medical Center-West Lakes
-
-
Kansas
-
Garden City, Kansas, Forente stater, 67846
- Central Care Cancer Center - Garden City
-
Great Bend, Kansas, Forente stater, 67530
- Central Care Cancer Center - Great Bend
-
-
Kentucky
-
Bardstown, Kentucky, Forente stater, 40004
- Flaget Memorial Hospital
-
Corbin, Kentucky, Forente stater, 40701
- Commonwealth Cancer Center-Corbin
-
Lexington, Kentucky, Forente stater, 40504
- Saint Joseph Radiation Oncology Resource Center
-
Lexington, Kentucky, Forente stater, 40509
- Saint Joseph Hospital East
-
London, Kentucky, Forente stater, 40741
- Saint Joseph London
-
Louisville, Kentucky, Forente stater, 40202
- Jewish Hospital
-
Louisville, Kentucky, Forente stater, 40245
- UofL Health Medical Center Northeast
-
Louisville, Kentucky, Forente stater, 40215
- Saints Mary and Elizabeth Hospital
-
Shepherdsville, Kentucky, Forente stater, 40165
- Jewish Hospital Medical Center South
-
-
Maryland
-
Baltimore, Maryland, Forente stater, 21237
- MedStar Franklin Square Medical Center/Weinberg Cancer Institute
-
-
Minnesota
-
Rochester, Minnesota, Forente stater, 55905
- Mayo Clinic in Rochester
-
-
Missouri
-
Ballwin, Missouri, Forente stater, 63011
- Saint Louis Cancer and Breast Institute-Ballwin
-
Bolivar, Missouri, Forente stater, 65613
- Central Care Cancer Center - Bolivar
-
Branson, Missouri, Forente stater, 65616
- Cox Cancer Center Branson
-
Joplin, Missouri, Forente stater, 64804
- Freeman Health System
-
Joplin, Missouri, Forente stater, 64804
- Mercy Hospital Joplin
-
Rolla, Missouri, Forente stater, 65401
- Delbert Day Cancer Institute at PCRMC
-
Rolla, Missouri, Forente stater, 65401
- Mercy Clinic-Rolla-Cancer and Hematology
-
Saint Joseph, Missouri, Forente stater, 64506
- Heartland Regional Medical Center
-
Springfield, Missouri, Forente stater, 65807
- CoxHealth South Hospital
-
Springfield, Missouri, Forente stater, 65804
- Mercy Hospital Springfield
-
St Louis, Missouri, Forente stater, 63141
- Mercy Hospital Saint Louis
-
St Louis, Missouri, Forente stater, 63128
- Mercy Hospital South
-
St Louis, Missouri, Forente stater, 63109
- Saint Louis Cancer and Breast Institute-South City
-
Washington, Missouri, Forente stater, 63090
- Mercy Hospital Washington
-
-
Montana
-
Missoula, Montana, Forente stater, 59802
- Saint Patrick Hospital - Community Hospital
-
-
Nebraska
-
Grand Island, Nebraska, Forente stater, 68803
- CHI Health Saint Francis
-
Kearney, Nebraska, Forente stater, 68847
- CHI Health Good Samaritan
-
Lincoln, Nebraska, Forente stater, 68510
- Saint Elizabeth Regional Medical Center
-
Omaha, Nebraska, Forente stater, 68124
- Alegent Health Bergan Mercy Medical Center
-
Omaha, Nebraska, Forente stater, 68122
- Alegent Health Immanuel Medical Center
-
Omaha, Nebraska, Forente stater, 68130
- Alegent Health Lakeside Hospital
-
Omaha, Nebraska, Forente stater, 68131
- Creighton University Medical Center
-
Papillion, Nebraska, Forente stater, 68046
- Midlands Community Hospital
-
-
New York
-
New York, New York, Forente stater, 10016
- Laura and Isaac Perlmutter Cancer Center at NYU Langone
-
-
Ohio
-
Beavercreek, Ohio, Forente stater, 45431
- Indu and Raj Soin Medical Center
-
Boardman, Ohio, Forente stater, 44512
- Saint Elizabeth Boardman Hospital
-
Centerville, Ohio, Forente stater, 45459
- Miami Valley Hospital South
-
Centerville, Ohio, Forente stater, 45459
- Dayton Physicians LLC-Miami Valley South
-
Cincinnati, Ohio, Forente stater, 45220
- Good Samaritan Hospital - Cincinnati
-
Cincinnati, Ohio, Forente stater, 45242
- Bethesda North Hospital
-
Cincinnati, Ohio, Forente stater, 45236
- Oncology Hematology Care Inc-Kenwood
-
Cincinnati, Ohio, Forente stater, 45247
- TriHealth Cancer Institute-Westside
-
Cincinnati, Ohio, Forente stater, 45255
- TriHealth Cancer Institute-Anderson
-
Dayton, Ohio, Forente stater, 45409
- Miami Valley Hospital
-
Dayton, Ohio, Forente stater, 45415
- Dayton Physician LLC-Miami Valley Hospital North
-
Dayton, Ohio, Forente stater, 45415
- Miami Valley Hospital North
-
Findlay, Ohio, Forente stater, 45840
- Blanchard Valley Hospital
-
Findlay, Ohio, Forente stater, 45840
- Armes Family Cancer Center
-
Findlay, Ohio, Forente stater, 45840
- Orion Cancer Care
-
Franklin, Ohio, Forente stater, 45005-1066
- Atrium Medical Center-Middletown Regional Hospital
-
Franklin, Ohio, Forente stater, 45005
- Dayton Physicians LLC-Atrium
-
Greenville, Ohio, Forente stater, 45331
- Wayne Hospital
-
Greenville, Ohio, Forente stater, 45331
- Dayton Physicians LLC-Wayne
-
Kettering, Ohio, Forente stater, 45429
- Kettering Medical Center
-
Kettering, Ohio, Forente stater, 45409
- Greater Dayton Cancer Center
-
Springfield, Ohio, Forente stater, 45505
- Springfield Regional Medical Center
-
Springfield, Ohio, Forente stater, 45504
- Springfield Regional Cancer Center
-
Troy, Ohio, Forente stater, 45373
- Upper Valley Medical Center
-
Troy, Ohio, Forente stater, 45373
- Dayton Physicians LLC-Upper Valley
-
Warren, Ohio, Forente stater, 44484
- Saint Joseph Warren Hospital
-
Youngstown, Ohio, Forente stater, 44501
- Saint Elizabeth Youngstown Hospital
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Forente stater, 73120
- Mercy Hospital Oklahoma City
-
-
Oregon
-
Bend, Oregon, Forente stater, 97701
- Saint Charles Health System
-
Clackamas, Oregon, Forente stater, 97015
- Clackamas Radiation Oncology Center
-
Clackamas, Oregon, Forente stater, 97015
- Providence Cancer Institute Clackamas Clinic
-
Coos Bay, Oregon, Forente stater, 97420
- Bay Area Hospital
-
Newberg, Oregon, Forente stater, 97132
- Providence Newberg Medical Center
-
Portland, Oregon, Forente stater, 97213
- Providence Portland Medical Center
-
Portland, Oregon, Forente stater, 97225
- Providence Saint Vincent Medical Center
-
Redmond, Oregon, Forente stater, 97756
- Saint Charles Health System-Redmond
-
-
Pennsylvania
-
Chadds Ford, Pennsylvania, Forente stater, 19317
- Christiana Care Health System-Concord Health Center
-
Philadelphia, Pennsylvania, Forente stater, 19104
- University of Pennsylvania/Abramson Cancer Center
-
Pittsburgh, Pennsylvania, Forente stater, 15232
- University of Pittsburgh Cancer Institute (UPCI)
-
-
Texas
-
Bryan, Texas, Forente stater, 77802
- Saint Joseph Regional Cancer Center
-
-
Utah
-
Salt Lake City, Utah, Forente stater, 84112
- Huntsman Cancer Institute/University of Utah
-
-
Washington
-
Aberdeen, Washington, Forente stater, 98520
- Providence Regional Cancer System-Aberdeen
-
Bellingham, Washington, Forente stater, 98225
- PeaceHealth Saint Joseph Medical Center
-
Bremerton, Washington, Forente stater, 98310
- Harrison HealthPartners Hematology and Oncology-Bremerton
-
Bremerton, Washington, Forente stater, 98310
- Harrison Medical Center
-
Burien, Washington, Forente stater, 98166
- Highline Medical Center-Main Campus
-
Centralia, Washington, Forente stater, 98531
- Providence Regional Cancer System-Centralia
-
Edmonds, Washington, Forente stater, 98026
- Swedish Cancer Institute-Edmonds
-
Enumclaw, Washington, Forente stater, 98022
- Saint Elizabeth Hospital
-
Everett, Washington, Forente stater, 98201
- Providence Regional Cancer Partnership
-
Federal Way, Washington, Forente stater, 98003
- Saint Francis Hospital
-
Issaquah, Washington, Forente stater, 98029
- Swedish Cancer Institute-Issaquah
-
Kennewick, Washington, Forente stater, 99336
- Kadlec Clinic Hematology and Oncology
-
Lacey, Washington, Forente stater, 98503
- Providence Regional Cancer System-Lacey
-
Lakewood, Washington, Forente stater, 98499
- Saint Clare Hospital
-
Longview, Washington, Forente stater, 98632
- PeaceHealth Saint John Medical Center
-
Poulsbo, Washington, Forente stater, 98370
- Harrison HealthPartners Hematology and Oncology-Poulsbo
-
Seattle, Washington, Forente stater, 98107
- Swedish Medical Center-Ballard Campus
-
Seattle, Washington, Forente stater, 98122
- Swedish Medical Center-First Hill
-
Seattle, Washington, Forente stater, 98104
- Pacific Gynecology Specialists
-
Seattle, Washington, Forente stater, 98122-5711
- Swedish Medical Center-Cherry Hill
-
Sedro-Woolley, Washington, Forente stater, 98284
- PeaceHealth United General Medical Center
-
Shelton, Washington, Forente stater, 98584
- Providence Regional Cancer System-Shelton
-
Tacoma, Washington, Forente stater, 98405
- Franciscan Research Center-Northwest Medical Plaza
-
Vancouver, Washington, Forente stater, 98664
- PeaceHealth Southwest Medical Center
-
Walla Walla, Washington, Forente stater, 99362
- Providence Saint Mary Regional Cancer Center
-
Yelm, Washington, Forente stater, 98597
- Providence Regional Cancer System-Yelm
-
-
Wisconsin
-
Chippewa Falls, Wisconsin, Forente stater, 54729
- Marshfield Clinic-Chippewa Center
-
Eau Claire, Wisconsin, Forente stater, 54701
- Marshfield Medical Center-EC Cancer Center
-
Ladysmith, Wisconsin, Forente stater, 54848
- Marshfield Clinic - Ladysmith Center
-
Marshfield, Wisconsin, Forente stater, 54449
- Marshfield Medical Center-Marshfield
-
Minocqua, Wisconsin, Forente stater, 54548
- Marshfield Clinic-Minocqua Center
-
Rice Lake, Wisconsin, Forente stater, 54868
- Marshfield Medical Center-Rice Lake
-
Stevens Point, Wisconsin, Forente stater, 54482
- Marshfield Medical Center-River Region at Stevens Point
-
Wausau, Wisconsin, Forente stater, 54401
- Marshfield Clinic-Wausau Center
-
Weston, Wisconsin, Forente stater, 54476
- Marshfield Medical Center - Weston
-
Wisconsin Rapids, Wisconsin, Forente stater, 54494
- Marshfield Clinic - Wisconsin Rapids Center
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
-
Patient must have locally advanced unresectable stage IIIC or stage IV melanoma
-
Patient must have BRAF V600E or BRAF V600K tumor genotype based on a Clinical Laboratory Improvement Act (CLIA) approved assay
-
Patient must have serum LDH > Upper limit of normal per institution standards
-
Patient must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. Baseline measurements of sites of disease must be obtained within 3 weeks prior to study randomization
-
Patient must have been treated with prior immune checkpoint inhibitor therapy (anti PD-1 antibody, anti-CTLA-4 antibody or a combination regimen including either or both agents) either in the adjuvant or metastatic setting. Patient may have received investigational agents in combination with standard therapy, as long as it was adhering to the timeframes below
- Patient must have discontinued active immunotherapy (IL-2, interferon, anti-CTLA-4 antibody, anti-PD-1 antibody etc.) or chemotherapy at least 4 weeks prior to randomization
- Patient must have discontinued any oral targeted therapy at least 2 weeks prior to randomization
-
Patient may have been treated with prior adjuvant therapy including combined BRAF and MEK inhibitor therapy. Patients will be eligible if they tolerated this therapy and did not discontinue the therapy due to toxicity AND >= 6 months have elapsed since the end of adjuvant BRAF and MEK inhibition.
-
Patient may have been treated with prior chemotherapy or radiation therapy
-
Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
-
Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
-
All females of childbearing potential must have a blood test or urine study within 14 days prior to randomization to rule out pregnancy.
-
Women of childbearing potential and sexually active males must not expect to conceive or father children by using accepted and effective method(s) of contraception or abstaining from sexual intercourse for the duration of their participation in the study and for 4 months after the last dose of protocol treatment
-
Patient must have recovered from clinically significant reversible toxicities from previous treatment prior to randomization. Abnormal laboratory values may be grade 1, as long as they meet the eligibility criteria for organ and marrow function
-
Patient must be able to swallow and retain oral medication and must not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowels
-
Patient must have the ability to understand and the willingness to sign a written informed consent document. Patients with impaired decision-making capacity (IDMC) who have a legally authorized representative (LAR) or caregiver and/or family member available will also be considered eligible
-
Absolute neutrophil count >= 1,500/mcL (obtained =< 14 days prior to protocol randomization)
-
Platelets >= 100,000/mcL (obtained =< 14 days prior to protocol randomization)
-
Total bilirubin =< institutional upper limit of normal (ULN) (obtained =< 14 days prior to protocol randomization)
-
Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 3.0 x institutional ULN (obtained =< 14 days prior to protocol randomization)
-
Creatinine =< 1.5 x institutional ULN (obtained =< 14 days prior to protocol randomization)
-
Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
-
For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
-
Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
-
Patient with asymptomatic new or progressive brain metastases (active brain metastases) are eligible if the treating physician determines that CNS specific treatment is not required
- NOTE: Patient with treated brain metastases are eligible. No brain imaging is required, however, 1 week must elapse after gamma knife therapy. Patient treated with whole brain radiation that have been stable for 2 months are eligible. Patient are excluded if they have leptomeningeal disease or metastases causing spinal cord compression that are symptomatic or untreated or not stable (documented by imaging) for at least 3 months or requiring corticosteroids. Patients on a stable dose of corticosteroids for at least 1 month or who have been off of corticosteroids for at least 1 week are eligible
Exclusion Criteria:
-
Receiving any other investigational anticancer therapy during the period on study or the 4 weeks prior to randomization
-
Patients received BRAF and MEK inhibitor therapy in the metastatic setting
-
Patients who are experiencing an objective partial response to immunotherapy at the time of study enrollment
-
Pregnant or breast-feeding; due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used. A female of childbearing potential is defined as any woman, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)
-
A history of interstitial lung disease (ILD) or chronic pneumonitis
- NOTE: If there is radiographic evidence of ILD that is clinically insignificant and asymptomatic, the patient would be eligible
-
Porphyria or psoriasis due to risk of disease exacerbation unless the disease is well controlled and they are under the care of a specialist for the disorder who agrees to monitor the patient for exacerbations
-
Previously documented retinal vein occlusion
-
A history or evidence of increased cardiovascular risk including:
- Left ventricular ejection fraction (LVEF) < institutional lower limit of normal measured within 14 days prior to randomization
- A QT interval corrected for heart rate using the Bazett's formula >= 480 msec
- Current clinically significant uncontrolled arrhythmias. Exception: Patients with controlled atrial fibrillation for > 30 days prior to randomization are eligible
- Acute coronary syndromes (including myocardial infarction and unstable angina), coronary angioplasty, or stenting within 6 months prior to randomization
- Abnormal cardiac valve morphology (>= grade 2) documented by echocardiogram unless a cardiologist concludes the valve abnormality is not clinically significant. Patients with grade 1 abnormalities (i.e., mild regurgitation/stenosis) are eligible
- Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better
-
Serious concurrent infection or medical illness, including psychiatric disorders, which would jeopardize the ability of the patient to receive the treatment outlined in this protocol with reasonable safety
-
Receiving concurrent therapy for their tumor (i.e. chemotherapeutics or investigational agents). Radiotherapy delivered to palliate pain is allowed as long as it is not targeting a lesion that meets RECIST criteria for progression. Radiation therapy to the surgical bed with gamma knife radiotherapy while on treatment during the first cycle is allowed for small volume surgically resected brain metastases. Gamma knife radiotherapy for known active, asymptomatic small volume central nervous system (CNS) lesions may be performed during the first cycle while on study. Radiotherapy for new CNS lesions identified beyond the first cycle is not allowed on study
-
Immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to study drug, or excipients or to dimethyl sulfoxide (DMSO)
-
Prior cytochrome P450 enzyme -inducing anticonvulsant drugs (extended-interval aminoglycoside dosing [EIADs]) (i.e. phenytoin, carbamazepine, phenobarbital, primidone or oxcarbazepine) within 4 weeks prior to randomization
-
Current use of a prohibited medication described in the protocol due to potential drug-drug interaction
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Dobbelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Arm A (dabrafenib, trametinib, hydroxychloroquine)
Patients receive dabrafenib mesylate PO BID, trametinib dimethyl sulfoxide PO QD, and hydroxychloroquine sulfate PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. |
Given PO
Andre navn:
Given PO
Andre navn:
Given PO
Andre navn:
|
|
Aktiv komparator: Arm B (dabrafenib, trametinib, placebo)
Patients receive dabrafenib mesylate PO BID, trametinib dimethyl sulfoxide PO QD, and placebo PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. |
Given PO Given PO
Andre navn:
Given PO
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
One-year Progression-free Survival Rate
Tidsramme: Assessed every 2 months until 6 months after completion of study treatment, up to 1 year
|
Progression-free survival is defined as the time from randomization to progression or death, whichever occurs first. Progression is defined as appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions, or at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. One-year progression-free survival rate is estimated from the Kaplan-Meier progression-free survival curve. |
Assessed every 2 months until 6 months after completion of study treatment, up to 1 year
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Progression-free Survival
Tidsramme: Assessed every 2 months until 6 months after completion of study treatment, up to 3 years
|
Progression-free survival is defined as the time from randomization to progression or death, whichever occurs first. Progression is defined as appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions, or at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. |
Assessed every 2 months until 6 months after completion of study treatment, up to 3 years
|
|
Proportion of Patients With Best Overall Response
Tidsramme: Assessed every 2 months until 6 months after completion of study treatment, up to 3 years
|
Best overall response is defined as either complete response or partial response. Complete response is defined as disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm. Partial response is defined as persistence of one or more non-target lesion(s) and at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. |
Assessed every 2 months until 6 months after completion of study treatment, up to 3 years
|
|
Proportion of Patients With Complete Response
Tidsramme: Assessed every 2 months until 6 months after completion of study treatment, up to 3 years
|
Complete response is defined as disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm. |
Assessed every 2 months until 6 months after completion of study treatment, up to 3 years
|
|
Adverse Event Rate
Tidsramme: Assessed every 4 weeks while on treatment and for 30 days after the end of treatment, up to 3 years
|
Proportion of patients with treatment-related adverse events of grade 3 or higher. |
Assessed every 4 weeks while on treatment and for 30 days after the end of treatment, up to 3 years
|
|
Overall Survival
Tidsramme: Assessed every 2 months until 6 months after completion of study treatment, up to 3 years
|
Overall survival is defined as the time from randomization to death or date last known alive. |
Assessed every 2 months until 6 months after completion of study treatment, up to 3 years
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Ravi Amaravadi, ECOG-ACRIN Cancer Research Group
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- EA6191
- U10CA180820 (U.S. NIH-stipend/kontrakt)
- EA6191 (Annen identifikator: CTEP)
- NCI-2020-04552 (Registeridentifikator: CTRP (Clinical Trial Reporting Program))
- EA6191 (Annen identifikator: ECOG-ACRIN Cancer Research Group)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Individual participant data may be made available upon request as per the ECOG-ACRIN Data Sharing Policy.
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .